Geron Corporation (GERN)vsModerna Inc (MRNA)
GERN
Geron Corporation
$1.35
-1.46%
HEALTHCARE · Cap: $950.86M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 989% more annual revenue ($2.23B vs $204.56M). GERN leads profitability with a -33.1% profit margin vs -141.4%. GERN earns a higher WallStSmart Score of 29/100 (F).
GERN
Avoid29
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GERN.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
17.2% revenue growth
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -32.0% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GERN
The strongest argument for GERN centers on Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : GERN
The primary concerns for GERN are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GERN profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
GERN is growing revenue faster at 17.2% — sustainability is the question.
GERN generates stronger free cash flow (-16M), providing more financial flexibility.
Bottom Line
GERN scores higher overall (29/100 vs 21/100) and 17.2% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Geron Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?